190 related articles for article (PubMed ID: 30840166)
1. A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer.
Nguyen CTT; Petrelli F; Scuri S; Nguyen BT; Grappasonni I
Eur J Health Econ; 2019 Jul; 20(5):763-777. PubMed ID: 30840166
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Gu X; Zhang Q; Chu YB; Zhao YY; Zhang YJ; Kuo D; Su B; Wu B
Lung Cancer; 2019 Jan; 127():84-89. PubMed ID: 30642557
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC).
Lange A; Prenzler A; Frank M; Golpon H; Welte T; von der Schulenburg JM
BMC Pulm Med; 2014 Dec; 14():192. PubMed ID: 25471553
[TBL] [Abstract][Full Text] [Related]
7. Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial.
Hornberger J; Hirsch FR; Li Q; Page RD
Lung Cancer; 2015 May; 88(2):223-30. PubMed ID: 25804732
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review.
Chouaïd C; Crequit P; Borget I; Vergnenegre A
Clinicoecon Outcomes Res; 2015; 7():9-15. PubMed ID: 25548525
[TBL] [Abstract][Full Text] [Related]
9. OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer.
Wen F; Zheng H; Zhang P; Hutton D; Li Q
BMJ Open; 2018 Apr; 8(4):e020128. PubMed ID: 29654023
[TBL] [Abstract][Full Text] [Related]
10. Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.
Vergnenegre A; Massuti B; de Marinis F; Carcereny E; Felip E; Do P; Sanchez JM; Paz-Arez L; Chouaid C; Rosell R;
J Thorac Oncol; 2016 Jun; 11(6):801-7. PubMed ID: 26899757
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S.
Kumar G; Woods B; Hess LM; Treat J; Boye ME; Bryden P; Winfree KB
Lung Cancer; 2015 Sep; 89(3):294-300. PubMed ID: 26122345
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung.
Zhu J; He W; Ye M; Fu J; Chu YB; Zhao YY; Zhang YJ; Kuo D; Wu B
Future Oncol; 2018 Nov; 14(27):2833-2840. PubMed ID: 29878848
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
Plosker GL; Hurst M
Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review.
Bongers ML; Coupé VM; Jansma EP; Smit EF; Uyl-de Groot CA
Pharmacoeconomics; 2012 Jan; 30(1):17-34. PubMed ID: 22201521
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.
Borget I; Pérol M; Pérol D; Lavolé A; Greillier L; Dô P; Westeel V; Crequit J; Léna H; Monnet I; Le Caer H; Fournel P; Falchero L; Poudenx M; Vaylet F; Chabaud S; Vergnenegre A; Zalcman G; Chouaïd C;
BMC Cancer; 2014 Dec; 14():953. PubMed ID: 25511923
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy.
Khan I; Morris S; Hackshaw A; Lee SM
BMJ Open; 2015 Jul; 5(7):e006733. PubMed ID: 26137881
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China.
Liu Q; Luo X; Peng L; Yi L; Wan X; Zeng X; Tan C
BMJ Open; 2020 Nov; 10(11):e040691. PubMed ID: 33243806
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis.
Créquit P; Chaimani A; Yavchitz A; Attiche N; Cadranel J; Trinquart L; Ravaud P
BMC Med; 2017 Oct; 15(1):193. PubMed ID: 29082855
[TBL] [Abstract][Full Text] [Related]
19. Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea.
Lim EA; Lee H; Bae E; Lim J; Shin YK; Choi SE
PLoS One; 2016; 11(8):e0160155. PubMed ID: 27483001
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.
Klein R; Muehlenbein C; Liepa AM; Babineaux S; Wielage R; Schwartzberg L
J Thorac Oncol; 2009 Nov; 4(11):1404-14. PubMed ID: 19786904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
